Morgan Stanley Novavax Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Novavax Inc stock. As of the latest transaction made, Morgan Stanley holds 1,238,786 shares of NVAX stock, worth $10.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,238,786

Previous 1,977,940 37.37%

Holding current value

$10.9 Million

Previous $12.7 Million 38.44%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$5.43 - $7.74 $4.01 Million - $5.72 Million	-739,154 Reduced 37.37%	1,238,786 $7.8 Million
Q1 2025 May 15, 2025	SELL	$6.41 - $10.82 $19 Million - $32.1 Million	-2,962,175 Reduced 59.96%	1,977,940 $12.7 Million
Q4 2024 Feb 14, 2025	BUY	$7.22 - $14.68 $24.5 Million - $49.7 Million	3,387,896 Added 218.26%	4,940,115 $39.7 Million
Q3 2024 May 14, 2025	SELL	$10.71 - $17.11 $1.61 Million - $2.58 Million	-150,516 Reduced 8.84%	1,552,219 $19.6 Million
Q3 2024 Nov 14, 2024	SELL	$10.71 - $17.11 $1.61 Million - $2.58 Million	-150,516 Reduced 8.84%	1,552,219 $19.6 Million
Q2 2024 May 14, 2025	SELL	$3.89 - $20.97 $12.6 Million - $67.9 Million	-3,237,380 Reduced 65.53%	1,702,735 $21.6 Million
Q2 2024 Oct 17, 2024	SELL	$3.89 - $20.97 $651,944 - $3.51 Million	-167,595 Reduced 8.96%	1,702,735 $21.6 Million
Q2 2024 Aug 14, 2024	SELL	$3.89 - $20.97 $651,944 - $3.51 Million	-167,595 Reduced 8.96%	1,702,735 $21.6 Million
Q1 2024 Oct 17, 2024	BUY	$3.76 - $6.02 $630,157 - $1.01 Million	167,595 Added 9.84%	1,870,330 $8.94 Million
Q1 2024 Aug 16, 2024	SELL	$3.76 - $6.02 $20.2 Million - $32.3 Million	-5,371,125 Reduced 74.17%	1,870,330 $8.94 Million
Q1 2024 May 15, 2024	SELL	$3.76 - $6.02 $20.2 Million - $32.3 Million	-5,371,125 Reduced 74.17%	1,870,330 $8.94 Million
Q4 2023 Aug 16, 2024	BUY	$4.8 - $7.67 $26.6 Million - $42.5 Million	5,538,720 Added 325.28%	7,241,455 $34.8 Million
Q4 2023 Feb 13, 2024	BUY	$4.8 - $7.67 $23.8 Million - $38.1 Million	4,966,324 Added 218.29%	7,241,455 $34.8 Million
Q3 2023 Nov 15, 2023	BUY	$6.81 - $9.74 $1.33 Million - $1.9 Million	194,694 Added 9.36%	2,275,131 $16.5 Million
Q2 2023 Aug 14, 2023	SELL	$6.67 - $9.52 $2.49 Million - $3.55 Million	-373,402 Reduced 15.22%	2,080,437 $15.5 Million
Q1 2023 May 15, 2023	BUY	$5.76 - $12.48 $3.88 Million - $8.42 Million	674,445 Added 37.9%	2,453,839 $17 Million
Q4 2022 Feb 14, 2023	BUY	$8.86 - $25.04 $6.07 Million - $17.2 Million	685,214 Added 62.62%	1,779,394 $18.3 Million
Q3 2022 Nov 14, 2022	SELL	$18.2 - $76.12 $3.49 Million - $14.6 Million	-192,009 Reduced 14.93%	1,094,180 $19.9 Million
Q2 2022 Oct 27, 2022	BUY	$36.28 - $75.29 $13.9 Million - $28.9 Million	383,415 Added 42.47%	1,286,189 $66.1 Million
Q2 2022 Aug 15, 2022	BUY	$36.28 - $75.29 $13.9 Million - $28.9 Million	383,415 Added 42.47%	1,286,189 $66.1 Million
Q1 2022 Oct 27, 2022	SELL	$69.73 - $142.9 $26.7 Million - $54.8 Million	-383,415 Reduced 29.81%	902,774 $66.5 Million
Q1 2022 May 13, 2022	SELL	$69.73 - $142.9 $3.75 Million - $7.68 Million	-53,718 Reduced 5.62%	902,774 $66.5 Million
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $36.4 Million - $59 Million	270,868 Added 39.51%	956,492 $137 Million
Q3 2021 Nov 15, 2021	BUY	$177.8 - $270.58 $122 Million - $186 Million	685,624 New	685,624 $142 Million

Others Institutions Holding NVAX

# of Institutions

313

Shares Held

94.4M

Call Options Held

6.11M

Put Options Held

10.5M

View Full List

About NOVAVAX INC

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $688M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

More about NVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account